KARPAS-299

Cat.No.: CSC-C7094J

Species: Homo sapiens (Human)

Source: Blood; Peripheral Blood

Morphology: Lymphoblastoid

Culture Properties: Suspension

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C7094J
Description
established from the peripheral blood of a 25-year-old man with T cell non-Hodgkin's lymphoma
Species
Homo sapiens (Human)
Source
Blood; Peripheral Blood
Recommended Medium
80% RPMI 1640 + 20% FBS
Culture Properties
Suspension
Morphology
Lymphoblastoid
Application
Immunology research
Cancer research
Size
1 Frozen Vial
Disease
Anaplastic Large Cell Lymphoma
Storage
Directly and immediately transfer cells from dry ice to liquid nitrogen upon receiving and keep the cells in liquid nitrogen until ready for use.
Shipping
Dry Ice
Restricted Use
For research use only. Not for use in diagnostic procedures.
Quality Control
All cells test negative for mycoplasma, bacteria, yeast, and fungi.
BioSafety Level
BSL-1
Synonyms
KARPAS-299; Karpas 299; KARPAS 299; Karpas299; KARPAS299; K299
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

KARPAS-299 is a well-characterized human T-cell lymphoma cell line originally established in 1986 from the peripheral blood of a 25-year-old male patient diagnosed with CD30+ anaplastic large cell lymphoma (ALCL). As one of the most extensively validated models in lymphoma research, KARPAS-299 has become a gold-standard platform for oncology drug discovery and translational studies.

The defining molecular hallmark of KARPAS-299 is the chromosomal translocation t(2;5)(p23;q35), which drives constitutive expression of the NPM-ALK fusion oncogene - a central driver of ALCL pathogenesis. The cell line robustly co-expresses CD30 (Ki-1 antigen) and ALK protein, making it uniquely suited for evaluating CD30- and ALK-directed therapeutics.

KARPAS-299 grows in suspension with a doubling time of ~30 hours, enabling rapid and reproducible experimental workflows. It maintains stable marker expression across passages and reliably engrafts in immunodeficient mice (NOD/SCID), forming consistent subcutaneous xenograft tumors - a critical advantage for in vivo preclinical efficacy studies.

GANT61 Induces Apoptosis in ALK-Positive Anaplastic Large Cell Lymphoma via Modulating the Hh-PIK3IP1-Akt Signaling Axis

This study aimed to initially characterize the effects of GANT61, a Hedgehog (Hh) signaling pathway inhibitor, on the biological behaviors of ALK-positive anaplastic large cell lymphoma (ALK + ALCL) cell lines and explore its underlying mechanisms.

GANT61 treatment promoted apoptosis in a dose- and time-dependent manner, as demonstrated by flow cytometric analysis (Fig. 1a and b). Dose- and time-dependent modulation of apoptosis regulators was demonstrated through western blot analysis, wherein GANT61 treatment downregulated Bcl-2 and caspase-3 expression, while upregulating Bax and cleaved caspase-3 levels (Fig. 1c-f).

Given the identified PI3K-Akt pathway activation in ALK + ALCL, we hypothesized that GANT61 might exert therapeutic effects through modulation of this signaling axis. Protein expression levels of Gli1, PIK3IP1, Akt and p-Akt were analyzed by western blot, while the mRNA expression of Gli1, Akt, and PIK3IP1 was quantified by qRT-PCR. GANT61 treatment increased PIK3IP1 protein level while decreasing Gli1 expression and p-Akt/Akt in both cell lines (Fig. 2a, b, d, e). These protein-level changes were corroborated at the transcriptional level, qRT-PCR showed upregulation of PIK3IP1 mRNA and downregulation of both Gli1 and Akt mRNA (Fig. 2c, f). These findings indicate that the Hh-PIK3IP1-Akt signaling axis may participate in ALK + ALCL tumorigenesis, showing that conventional target drugs can be employed for ALK + ALCL treatment.

The effect of GANT61 on apoptosis in ALK + ALCL cell line Karpas-299.

Fig. 1. GANT61 promoted apoptosis in the Karpas-299 cell line (Chen, Hongyuan, et al., 2026).

The Gli inhibitor GANT61 disrupted the PI3K/Akt signaling pathway in ALK + ALCL cell lines.

Fig. 2. GANT61 disrupted the PI3K/Akt signaling pathway in ALK + ALCL cell lines (Chen, Hongyuan, et al., 2026).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products